Show Menu

A fully integrated developer and manufacturer of polyclonal therapeutics, targeting infectious disease and acute toxic events

Current Products

MicroPharm has a portfolio of five antivenom products and is developing several new immunotherapeutic products for human and veterinary use.

ViperaTAb®

Affinity Purified, European Viper Antivenom (solution for dilution for infusion).

Indication

European common adder (Vipera berus) envenomation.

Description

Although not an approved or marketed drug, ViperaTAb® is available in Europe on a named patient basis. ViperaTAb®, a Polyvalent Immune Fab (Ovine), comprises specific antibody fragments that bind and neutralise Vipera berus venom components, including proteases, lipases and cardiotoxins, facilitating their redistribution away from target tissues and subsequent elimination from the body.

ViperaTAb® is an antidote for the treatment of snakebites from the European common adder (Vipera berus). This product is currently available on a named patient basis in Europe under a distribution agreement with Flynn Pharma Limited.  For all product enquiries please contact Flynn Pharma.  For telephone enquiries, please see the following link https://www.flynnpharma.com/viperatab-contact-numbers; for written enquiries please see the following link https://www.flynnpharma.com/contact-us.

VIPERFAV®

Immunoglobulin F(ab’)2 fragments of equine origin (solution for dilution for infusion).

Indication

Indicated for the treatment of envenomation (grade II or III) by European vipers (Vipera aspis, Vipera berus, Vipera ammodytes).

Description

VIPERFAV is a preparation containing equine immunoglobulin F(ab’)2 fragments which have the property of neutralising the venom of three species of vipers: Vipera aspisVipera berusVipera ammodytes.

These equine immunoglobulin F(ab’)2 fragments fix the venom antigens present in the blood in the form of inactive F(ab’)2-antigen complexes, reducing the level of free venom in the blood.

The product has a Marketing Authorisation (34009 562 154 09) granted by ANSM.

VIPERFAV is distributed in France by Inresa Pharma (www.inresa-pharma.fr). For product enquires please contact Inresa Pharma. 

VIPERFAV is distributed in all other countries by Flynn Pharma (www.flynnpharma.com).  For product enquiries please contact Flynn Pharma. 

BOTHROFAV®

Immunoglobulin F(ab’)2 fragments of equine origin (solution for dilution for infusion).

Indication

Treatment of mild to major envenomation by Bothrops lanceolatus.

Description

BOTHROFAV is a preparation containing F(ab’)2 fragments which have the property of neutralising Bothrops lanceolatus venom.  These equine F(ab’)2 fragments ligate venom antigens present in the circulation to form inactive F(ab’)2-antigen complexes, reducing the amount fo free venom in the circulation.

The product has a Nominative ATU granted by ANSM.

For product enquires from customers in France please contact Inresa Pharma (www.inresa-pharma.fr).

For product enquiries from customers in other countries please contact MicroPharm.

SCORPIFAV®

Immunoglobulin F(ab’)2 fragments of equine origin (solution for dilution for infusion)

Indication

Indicated for the treatment of envenomation caused by venomous scorpion species found in North Africa and Middle East (Androctonus australis hector, Leiurus quinquestriatus, Buthus occitanus mardochei).

Description

SCORPIFAV is a highly purified preparation containing immunoglobulin F(ab’)2 fragments of equine origin which have the ability to neutralise venom from scorpions Androctonus australis hector, Leiurus quinquestriatus and Buthus occitanus mardochei.

For product enquires from customers in France please contact Inresa Pharma, France (www.inresa-pharma.fr).

For product enquiries from customers in other countries please contact MicroPharm.

EchiTAbG™

An antivenom for the treatment of envenomation by Echis ocellatus (carpet viper).

This product was developed in collaboration with the Nigerian Federal Ministry of Health.